Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | APAF1 | O14727 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | UBE2N | P61088 | 1/20 | 0.76 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11869688 | 0.99 | KDM4E (0.78) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL31187488 | 0.93 | KDM4E (0.82) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL29393496 | 0.91 | POLB (0.80) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL31151021 | 0.89 | EHMT2 (0.69) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL14877525 | 0.89 | KDM4E (0.76) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL30555731 | 0.88 | EHMT2 (0.68) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL11503536 | 0.87 | POLB (0.74) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL7796182 | 0.87 | KDM4E (0.90) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL31187491 | 0.87 | POLB (0.62) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Aminodimethoxyquinazolinylpiperazine SCHEMBL32690190 | 0.86 | KDM4E (1.00) | KDM4EAPAF1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0034471-A1 | Piperidinoquinazolines and a process for the preparation thereof | ORION-YHTYMÄ OY (FI) | 1981-08-26 | — | — | EP | claimed |
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| EP-1871345-B1 | NANOPARTICULATE ERLOTINIB FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2012-08-01 | — | — | EP | disclosed |
| EP-1871345-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | Elan Pharma International Limited (IE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | ELAN PHARMA INTERNATIONAL, LIMITED | 2006-11-02 | — | — | US | disclosed |
| WO-2006110811-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-10-19 | — | — | WO | disclosed |
| EP-0892790-B1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LAB (IT) | 2004-04-14 | — | — | EP | disclosed |
| EP-0034471-A1 | Piperidinoquinazolines and a process for the preparation thereof | ORION-YHTYMÄ OY (FI) | 1981-08-26 | — | — | EP | disclosed |
| EP-0034471-A1 | Piperidinoquinazolines and a process for the preparation thereof | ORION-YHTYMÄ OY (FI) | 1981-08-26 | — | — | EP | disclosed |
| US-3980650-A | 4-Amino-pyrimidine derivatives | N.V. KONINKLIJKE PHARMACEUTISCHE FABRIEKEN V/H BROCADES-STHEEMAN EN PHARMACIA (NL) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | KRAS, NRAS, ABL1 | KDM4E 3063/4885APAF1 4080/4885ALDH1A1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.